Novo Nordisk A/S (NVO)
Last Price$88.15.2%
Market Cap$392.3B
LTM P/E
27.7x
EPS growth
21.7%
PEGY
1.2x
Peter Lynch Fair Value
$74.1
Overvalued (Peter Lynch formula)
(15.8%)
Stock quality
7/10
Good
NVO Peter Lynch Fair Value
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
NVO EPS growth & Dividend Yield
Crunching data... Almost there!
NVO vs Peer Set: Peter Lynch Fair Value Comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for NVO
Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value
FAQ
What is Novo Nordisk A/S fair value by Peter Lynch formula?
As of Feb 21, 2025, Novo Nordisk A/S's fair value using the Peter Lynch formula is $74.1 per share. The current price of $88.1 suggests Novo Nordisk A/S may be overvalued by this metric.
What is Novo Nordisk A/S Price to Earnings (P/E) ratio?
As of Feb 21, 2025, Novo Nordisk A/S's P/E ratio is 27.7x. This is calculated by dividing the current share price of $88.1 by the Earnings per Share (EPS) for the trailing twelve months, which is $22.7. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
What is Novo Nordisk A/S earnings per share (EPS)?
Novo Nordisk A/S earnings per share (EPS) for the twelve months ending Feb 21, 2025, was $22.7, a 21.7% growth year-over-year.